Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801
Publication
, Conference
Stinchcombe, TE; Hodgson, L; Herndon, JE; Kelley, MJ; Cicchetti, M; Ramnath, N; Niell, HB; Atkins, JN; Green, MR; Vokes, EE
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2009
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
May 20, 2009
Volume
27
Issue
15
Location
Orlando, FL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
45th Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Stinchcombe, T. E., Hodgson, L., Herndon, J. E., Kelley, M. J., Cicchetti, M., Ramnath, N., … Vokes, E. E. (2009). Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 27). Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
Stinchcombe, T. E., L. Hodgson, J. E. Herndon, M. J. Kelley, M. Cicchetti, N. Ramnath, H. B. Niell, J. N. Atkins, M. R. Green, and E. E. Vokes. “Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
Stinchcombe TE, Hodgson L, Herndon JE, Kelley MJ, Cicchetti M, Ramnath N, et al. Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2009.
Stinchcombe, T. E., et al. “Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801.” JOURNAL OF CLINICAL ONCOLOGY, vol. 27, no. 15, AMER SOC CLINICAL ONCOLOGY, 2009.
Stinchcombe TE, Hodgson L, Herndon JE, Kelley MJ, Cicchetti M, Ramnath N, Niell HB, Atkins JN, Green MR, Vokes EE. Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2009.
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
May 20, 2009
Volume
27
Issue
15
Location
Orlando, FL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
45th Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences